Exosome Diagnostics
Exosome Diagnostics develops and commercializes blood- and urine-based liquid biopsy tests for prostate cancer, using proprietary exosome profiling technology to support biopsy decision-making. Founded in 2008 and acquired by MDxHealth in September 2025, the company serves urologists, oncologists, and patients across U.S. CLIA-certified laboratories.
- Company typePrivate
- Founded2008
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Exosome Diagnostics does
Exosome Diagnostics is a molecular diagnostics company that develops and commercializes blood- and urine-based liquid biopsy tests for cancer, with a primary focus on prostate cancer patient stratification and biopsy decision support. Founded in 2008 and originally headquartered in San Diego (later moving to New York), the company's proprietary technology isolates and analyzes tumor-derived exosomes from bodily fluids, enabling non-invasive detection of cancer-related molecular signals. Its flagship product, the ExoDx Prostate Test (now branded Exo mdx following the MDxHealth acquisition), is supported by Level 1 clinical evidence and offers at-home specimen collection, addressing the clinical challenges of false-negative biopsies and overdiagnosis of indolent prostate cancer. The company operates CLIA-certified and CAP-accredited laboratory facilities, with regulatory licensure extending to New York State and Health Canada.
The business model centers on diagnostic testing services billed through insurance, supplemented by patient financial assistance programs including interest-free payment plans. Exosome Diagnostics serves urologists, oncologists, and men with suspected or diagnosed prostate cancer as primary customers, with a secondary use case in infectious disease testing. Go-to-market relies on physician outreach, clinical education webinars, and direct patient engagement, operating as a B2B2C model where physician recommendation drives test adoption. Pricing is not publicly disclosed but the company emphasizes accessibility through patient assistance infrastructure.
Exosome Diagnostics was historically loss-making, having raised over $112 million in equity financing across multiple rounds (2010-2017) from investors including Forbion Capital Partners, NGN Capital, Qiagen, and Tiger Infrastructure Partners. The company operated as a subsidiary of Bio-Techne Corporation before being acquired by MDxHealth SA in September 2025 for up to $15 million in stock and contingent payments. Following the acquisition, Exosome Diagnostics now operates as a wholly-owned subsidiary within MDxHealth's prostate cancer molecular diagnostics platform, which also includes Confirm mdx, GPS mdx, Select mdx, and Resolve mdx.
Exosome Diagnostics firmographics
Firmographics- Name
- Exosome Diagnostics
- Legal name
- Exosome Diagnostics Inc.
- Website
- https://exosomedx.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Exosome Diagnostics develops and commercializes blood- and urine-based liquid biopsy tests for prostate cancer, using proprietary exosome profiling technology to support biopsy decision-making. Founded in 2008 and acquired by MDxHealth in September 2025, the company serves urologists, oncologists, and patients across U.S. CLIA-certified laboratories.
- Ownership category
- akta.pro rank
Exosome Diagnostics industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Exosome Diagnostics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Exosome Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Testing Services: MDxHealth generates revenue through laboratory diagnostic testing services. The company offers multiple prostate cancer tests including Exo mdx, Confirm mdx, and GPS mdx. Revenue increased 18% in Q3 2025 to $27.4 million following the acquisition of Exosome Diagnostics. Tests are billed through insurance and include patient assistance programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Patient Financial Assistance Program |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Exosome Diagnostics product offering
Product offeringCore offering
Exosome Diagnostics develops and commercializes exosome-based liquid biopsy molecular diagnostic tests, principally the ExoDx Prostate Test (now branded Exo mdx), which analyzes tumor-derived exosomes in urine to non-invasively stratify patients for prostate biopsy decision-making. Tests are processed through a CLIA-certified laboratory and supported by Level 1 clinical evidence with at-home specimen collection available.
Product overview
MDxHealth acquired Exosome Diagnostics Inc. in September 2025, adding the Exo mdx (formerly ExoDx) liquid biopsy test to its portfolio of prostate cancer molecular diagnostics. The company's product suite includes tissue-based tests (Confirm mdx, GPS mdx), liquid biopsy tests (Exo mdx), infectious disease tests (Resolve mdx), and Select mdx, forming an integrated diagnostic pathway for urologic diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Exo mdx (formerly ExoDx Prostate Test) A liquid biopsy urine test for prostate cancer that uses exosome-based molecular profiling to enhance and simplify patient stratification for prostate biopsy decision-making. Supported by Level 1 Evidence with at-home specimen collection available. Intended for use by urologists, oncologists, and their patients with suspected or diagnosed prostate cancer.
Quantifiable outcome
- Non-invasive liquid biopsy reduces need for invasive tissue biopsies
- +1 more outcomes
Companies that use Exosome Diagnostics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Exosome Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Exosome Diagnostics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
Exosome Diagnostics competitors and assessment
Company assessmentBroad incumbents
- MDxHealth: MDxHealth is the parent acquirer of Exosome Diagnostics and operates an overlapping prostate-cancer molecular diagnostics portfolio (Confirm mdx, GPS mdx, Select mdx, Resolve mdx), making it the most directly comparable commercial platform in urologic molecular diagnostics.
- Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based NGS tests across multiple cancers. Comparable to Exosome Diagnostics in the liquid biopsy modality and CLIA-laboratory model, though operating at significantly greater scale across indications.
- Exact Sciences (now Exact Sciences Corp.): Exact Sciences operates Oncotype DX and Cologuard and has expanded into liquid biopsy through the Thrive acquisition. Comparable as a molecular diagnostics company with urologic and oncology tests run through a CLIA-certified lab.
- Bio-Techne: Bio-Techne was the prior owner of Exosome Diagnostics and divested it to MDxHealth in September 2025. Bio-Techne supplies exosome research tools and reagents, making it a thematic peer in the exosome-based research and diagnostics ecosystem.
Direct peers
- Natera: Natera offers Signatera, a tumor-informed liquid biopsy MRD test, and runs a CLIA-certified lab serving urology and oncology. Direct competitor to Exosome Diagnostics in the liquid biopsy oncology space with overlapping physician customer base.
- NeoGenomics: NeoGenomics operates a large oncology-focused clinical laboratory with a broad menu of molecular and genetic tests, including liquid biopsy offerings. Comparable in operating model, CLIA lab footprint, and customer base (oncologists, urologists).
- Personal Genome Diagnostics (PGDx): PGDx develops tissue-based and liquid biopsy cancer genomic tests for therapy selection and monitoring. Direct comparable in liquid biopsy oncology diagnostics with a CLIA lab and similar B2B2C go-to-market through oncologists and urologists.
Emerging players
- GRAIL: GRAIL develops Galleri, a multi-cancer early detection blood test using methylation-based cfDNA analysis. Comparable to Exosome Diagnostics as a blood-based cancer screening/early-detection liquid biopsy platform, though focused on multi-cancer rather than prostate specifically.
- Biocept: Biocept offers liquid biopsy tests (Target Selector) for cancer biomarker analysis using ctDNA and CTCs. Comparable as a smaller liquid biopsy oncology diagnostic company with overlapping technology approaches and a similar clinical laboratory operating model.
- Angle plc: Angle plc is developing a liquid biopsy platform using circulating tumor cells (Parsortix) for cancer diagnostics and monitoring. Comparable as an emerging liquid biopsy oncology diagnostics company with proprietary sample-prep technology.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Exosome Diagnostics social profiles
Digital presenceExosome Diagnostics compliance and trust
Trust signalCompliance4 records
Exosome Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exosome Diagnostics leadership team
Management profileNumber of profiles
Profiles4 records
Exosome Diagnostics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exosome Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exosome Diagnostics
What does Exosome Diagnostics do?
Exosome Diagnostics develops and commercializes exosome-based liquid biopsy molecular diagnostic tests, principally the ExoDx Prostate Test (now branded Exo mdx), which analyzes tumor-derived exosomes in urine to non-invasively stratify patients for prostate biopsy decision-making. Tests are processed through a CLIA-certified laboratory and supported by Level 1 clinical evidence with at-home specimen collection available.
Is Exosome Diagnostics a public or private company?
Exosome Diagnostics is a private company. It is classified as corporate owned and is currently acquired.
When was Exosome Diagnostics founded?
Exosome Diagnostics was founded in 2008. It employs 51 to 100 people.
Where is Exosome Diagnostics based?
Exosome Diagnostics is headquartered in New York, United States, in the North America region.
How does Exosome Diagnostics make money?
One revenue line is on record: diagnostic Testing Services.
Who are Exosome Diagnostics's main competitors?
Broad incumbents on record are MDxHealth, Guardant Health, Exact Sciences (now Exact Sciences Corp.) and Bio-Techne. Direct peers are Natera, NeoGenomics and Personal Genome Diagnostics (PGDx). Emerging players are GRAIL, Biocept and Angle plc.
Does Exosome Diagnostics have an API?
No public API is recorded for Exosome Diagnostics.
What industry is Exosome Diagnostics in?
Exosome Diagnostics's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.